The tachykinin NK1 receptor. Part I: Ligands and mechanisms of cellular activation

Neuropeptides

Volumn 31, Issue 6, 1997, Pages 537-563

  Quartara, L ^a   Maggi, C A ^a  

^a Menarini Ricerche SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

17ALPHA ETHYNYL 17BETA HYDROXY 5ALPHA ANDROSTANO[3,2 B]PYRIMIDO[1,2 A]BENZIMIDAZOLE; 2 BENZHYDRYL 3 (2 METHOXYBENZYLAMINO) 1 AZABICYCLO[2.2.2]OCTANE; 2 [1 IMINO 2 (2 METHOXYPHENYL)ETHYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 ONE; 2 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 4 (3 OXO 1,2,4 TRIAZOL 5 YLMETHYL) 3 PHENYLMORPHOLINE; 3 (2 METHOXY 5 TRIFLUOROMETHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; 3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYLPIPERIDINE; 4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 5 AMINOVALERYLSUBSTANCE P [7-11][9 PROLINE 10 (N METHYLLEUCINE)]; 5 [[3 [3,5 BIS(TRIFLUOROMETHYL)BENZYLOXY] 2 PHENYL 1 PIPERIDINYL]METHYL] 1,2 DIHYDRO 3H 1,2,4 TRIAZOL 3 ONE; FR 113680; GUANINE NUCLEOTIDE BINDING PROTEIN; INOSITOL PHOSPHATE; ION CHANNEL; L 709210; L 7333060; LIGAND; MEN 11930; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; NOLPITANTIUM; PIPERIDINE DERIVATIVE; QUINUCLIDINE DERIVATIVE; RP 100893; RP 73467; S 18523; SEPTIDE; SPANTIDE; SUBSTANCE P; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; VOFOPITANT; [2 METHOXY 5 (1 TETRAZOLYL)BENZYL](2 PHENYL 3 PIPERIDINYL)AMINE; NEUROKININ 1 RECEPTOR;

ARTICLE; CELL ACTIVATION; INTERNALIZATION; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING; SCREENING; STRUCTURE ACTIVITY RELATION; TACHYPHYLAXIS; ANIMAL; BINDING SITE; CHANNEL GATING; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN; METABOLISM; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

MAMMALIA;

ANIMALS; BINDING SITES; HUMANS; ION CHANNEL GATING; LIGANDS; RECEPTORS, NEUROKININ-1; SIGNAL TRANSDUCTION;

EID: 0031283503     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(97)90001-9     Document Type: Article

References (154)

1. Henry J L. Discussion of nomenclature for TKs and tachykinin receptors. Substance P and Neurokinins. New York: Springer-Verlag, 1987: xvii.
2. Lee C M, Campbell N J, Williams B J, Iversen L L. Molecular characterization of a functional cDNA for rat receptor. Eur J Pharmacol 1986; 130: 209-217.
3. Regoli D, Drapeau G, Dion S, D'Orlean-Juste P. Pharmacological receptors for substance P and neurokinins. Life Sci 1987; 40: 109-117.
4. Maggi C A, Giuliani S, Santicioli P, Regoli D, Meli A. Peripheral effects of neurokinins: functional evidence for the existence of multiple receptors. J Auton Pharmacol 1987; 7: 243-255.
5. Yokota Y, Sasai Y, Tanaka K, et al. Molecular characterization of a functional cDNA for rat receptor. J Biol Chem 1989; 264: 17469-17652.
6. Hershey A D, Krause J E. Molecular characterization of a functional cDNA encoding the rat substance P receptor. Science 1990; 247: 958-962.
7. Maggi C A, Patacchini R, Rovero P, Giachetti A. Tachykinin receptors and receptor antagonists. J Auton Pharmacol 1993; 13: 958-962.
8. Regoli D, Boudon A, Fauchere J. Receptors and antagonists for substance P and related peptides. Pharmacol Rev 1994; 46(4): 551-599.
9. Lowe III J A, McLean S. Tachykinin antagonists. Current Pharmaceutical Design 1995; 1(3): 269-278.
10. Maggi C A. The mammalian tachykinin receptors. Gen Pharmacol 1995; 26(5): 911-944.
11. Cascieri M A, Huang R C, Fong T M et al. Determination of the amino acid residues in substance P conferring selectivity and specificity for the rat neurokinin receptors. Mol Pharmacol 1992; 41: 1096-1099.
12. Sandberg B E, Lee C M, Hanley M R, Iversen L L. Synthesis and biological properties of enzyme resistant substance P analogues. Eur J Biochem 1981; 114: 329-337.
13. Drapeau G, D'Orlean-Juste P, Dion S, Rhaleb N, Rouissi N E, Regoli D. Specific agonists for substance P and neurokinin receptors. Neuropeptides 1987; 10: 43-45.
14. Harbeson S L, Rovero P. Structure-activity relationships of agonist and antagonist ligands. In: Buck S H. The tachykinin receptors. New Jersey: Totowa, 1994: Ch 12.
15. 9SP(6-11), a selective agonist for the substance P receptor subtype. J Med Chem 1986; 29: 1284-1288.
16. Hagan R M, Ireland S J, Jordan C C et al. Novel, potent and selective agonists at NK-1 and NK-2 receptors. Br J Pharmacol 1989; 98: 717P.
17. 6]-SP6-11 by benzyl ester groups. Int J Pept Protein Res 1993; 42: 565-569.
18. Gilon C, Halle D, Chorev M, Selinger Z, Byk G. Backbone cyclization: a new method for conferring conformational constraint on peptides. Biopolymers 1991; 31: 745-750.
19. Byk G, Halle D, Zeltser I, Bitan G, Selinger Z, Gilon C. Synthesis and biological activity of NK-1 selective, N-backbone cyclic analogs of the C-terminal hexapeptide of substance P. J Med Chem 1996; 39(16): 3174-3178.
20. Ward P, Ewan G B, Jordan C C, Ireland S J, Hagan R M, Brown J R. Potent and highly selective neurokinin antagonists. J Med Chem 1990; 33(7): 1848-1851.
21. Deal M J, Hagan R M, Ireland S J et al. Conformationally constrained tachykinin analogues: potent and highly selective neurokinin NK-2 receptor agonists. J Med Chem 1992; 35(22): 4195-4204.
22. Folkers K, Hakanson R, Horig J, Jie-Cheng X, Leander S. Biological evaluation of substance P antagonists. Br J Pharmacol 1984; 83: 449-456.
23. Folkers K, Feng D, Asano N, Hakanson R, Weisenfeld-Hallin Z, Leander S. Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity. Proc Natl Acad Sci USA. 1990; 87: 4833-4835.
24. Karagiannis K, Manolopoulou A, Poulos C, Stavropoulos G. Synthesis of substance P C-terminal hexapeptide analogues and their biological activity. Analogues with antagonist activity without containing D-amino acids. Eur J Med Chem 1994; 29: 667-673.
25. Paladino J, Thurieau C, Morris A D et al. Synthesis and in vitro activities of new tryptophan-modified and thiomethylene-containing pseudopeptide antagonists of the neurokinins. Int J Pept Protein Res 1993; 42: 284-293.
26. Lavielle S, Brunissen A, Carruette A, Garret C, Chassaing G. Highly potent substance P antagonists substituted with β-phenyl or β-benzyl-proline at position 10. Eur J Pharmacol 1994; 258: 273-276.
27. Hirschmann R, Nicolaou K C, Pietranico S et al. Nonpeptidal peptidomimetics with a b-D-glucose scaffolding. A partial somatostatin agonist bearing a close structural relationship to a potent, selective substance P antagonist. J of the Am Chem Soc 1992; 114: 9217-9218.
28. Hirschmann R, Yao W, Cascieri M A, et al. Synthesis of potent cyclic hexapeptide NK-1 antagonists. Use of a minilibrary in transforming a peptidal somatostatin receptor ligand into an NK-1 receptor ligand via a polyvalent peptidomimetic. J Med Chem 1996; 39(13): 2441-2448.
29. Pinori M, Cappelletti S, Di Gregorio G, Porcelli M, Murgia G, Mascagni P. Conformation of new cyclopentapeptide neurokinin antagonists in solution. Peptides: chemistry, structure and biology. Proceedings of the fourteenth American Peptide Symposium. England: Mayflower Scientific, 1996: 497-498.
30. Hashimoto M, Hayashi K, Murai M, et al. WS9326A, a novel tachykinin antagonist isolated from Streptomices Violaceuniger No. 9326. II. Biological and pharmacological properties of WS9326A and tetrahydro-WS9326A (FK224). J Antibiot 1992; 45: 1064.
31. Williams B J, Curtis N R, McKnight A T et al. Cyclic peptides as selective tachykinin antagonists. J Med Chem 1993; 36(1): 2-10.
32. Hagiwara D, Miyake H, Moromoto H, Murai M, Fujii T, Matsuo M. Studies on neurokinin antagonists. 1. The design of novel tripeptides possessing the glutaminyl-D-tryptophylphenyl-alanine sequence as substance P antagonists. J Med Chem 1992; 35: 2015-2025.
33. Hagiwara D, Miyake H, Moromoto H, Murai M, Fujii T, Matsuo M. Studies on neurokinin antagonists. 2. Design and structure-activity relationships of novel tripeptide substance P antagonists, Nα-[Nα-(Nα-Acetyl-L-threonyl)-N1-formyl-D-tryptophyl]-N- methyl-N-(phenyl-methyl)-L-phenylalaninamide and its related compounds. J Med Chem 1992; 35: 3184-3191.
34. Hagiwara D, Miyake H, Murano K et al. Studies on neurokinin antagonists. 3. Design and structure-activity relationships of new branched tripeptides Nα-(substituted L-aspartyl, L-ornithyl or L-lysyl)-N-methyl-N-(phenylmethyi)-L-phenylalaninamide as substance P antagonists. J Med Chem 1993; 36(16): 2266-2278.
35. Hagiwara D, Miyake H, Igari N, et al. Studies on neurokinin antagonists. 4. Synthesis and structure-activity relationships of novel dipeptide substance P antagonists: N2-[(4R)-4-hydroxy-1-[(1-methyl-1H-indol-3-yl)carbonyl]-L-prolyl]-N-methyl-N- (phenylmethyl)-3-(2-naphthyl)-L-alaninamide and its related compounds. J Med Chem 1994; 37: 2090-2099.
36. Bonnet J, Kucharczyk N, Robineau P et al. A water-soluble, stable dipeptide NK1 receptor-selective neurokinin receptor antagonist with potent in vivo pharmacological effects: S18523. Eur J Pharmacol 1996; 310: 37-46.
37. Sisto A, Bonelli F, Centini F et al. Synthesis and biological evaluation of novel NK-1 tachykinin receptor antagonists: the us of cycloalkyl amino acids as a template. Biopolymers 1995; 36: 511-524.
38. Sisto A, Arcamone F, Centini F et al. Rational design of cycloalkyl amino acid based peptido-mimetics. Synthesis of novel NK-1 tachykinin receptor antagonists. Peptides: chemistry, structure and biology. Proceedings of the fourteenth American Peptide Symposium. England: Mayflower Scientific, 1996: 713-714.
39. 1 tachykinin receptor antagonists. Peptides: chemistry, structure and biology. Proceedings of the fourteenth American Peptide Symposium. England: Mayflower Scientific, 1996: 229-230.
40. Appell L E, Babb B E, Goswami R et al. Imidazo[4, 5-b]quinoxaline Cyanines as neurokinin antagonists. J Med Chem 1991; 34(5): 1751-1753.
41. Lawrence K B, Venepalli B R, Appell K C et al. Synthesis and substance P antagonist activity of naphtimidazolium derivatives. J Med Chem 1992; 35(7): 1273-1279.
42. Venepalli B R, Aimone L D, Appell K C et al. Synthesis and substance P receptor binding activity of androstano[3, 2-b]pyrimido[1, 2-a]benzimidazoles. J Med Chem 1992; 35: 374-378.
43. Garret C, Carruette A, Fardin V et al. Pharmacological properties of a potent and selective nonpeptide Substance P antagonist. Proc Natl Acad Sci USA. 1991; 88: 10208-10212.
44. Beaujouan J, Heuillet E, Petitet F, Saffroy M, Torrens Y, Glovinski J. Higher potency of RP 67580, in the mouse and the rat compared with other nonpeptide and peptide tachykinin NK1 antagonists. Br J Pharmacol 1993; 108: 793-800.
45. Grisoni S, Huon C, Peyronel J. 4, 4-diphenyl-7-perhydrothiopyrano[3, 4-c]pyrrolone, a new series of substance P receptors antagonists. Biomed Chem Lett 1995; 5(15): 1591-1594.
46. Tabart M, Peyronel J. Synthesis of RPR 100893, prototype of a new series of potent and selective non peptide NK1 antagonists: the triarylperhydroisoindolols. Biomed Chem Lett 1994; 4(5): 673-676.
47. Snider R M, Constantine J W, Lowe III J A et al. A potent nonpeptide antagonist of the Substance P (NK1) receptor. Science 1991; 251: 435-437.
48. Lowe I J A, Drozda S E, Snider R M et al. The discovery of (2S, 3S)-cis-2-(Diphenylmethyl)-N-[(2-methoxyphenyl)methyl]-1-azabicyclo[2.2.2]- octan-3-amine as a novel, nonpeptide substance P antagonist. J Med Chem 1992; 35: 2591-2600.
49. 1) receptor antagonist. Science 1991; 251: 437-439.
50. 1) antagonist, CP-96, 345. Biomed Chem Lett 1992; 2(6): 559-564.
51. Lowe III J A, Drozda S E, Snider R M, Longo K P, Rizzi J P. Nuclear variations of quinuclidine substance P antagonists: 2-diphenylmethyl-1-azabicyclo[3.2.2]nonan-3-amines. Biomed Chem Lett 1993; 3(921-924).
52. Lowe III J A, Drozda S E, McLean S et al. Aza-tricyclic substance P antagonists. J Med Chem 1994; 37(18): 2831-2840.
53. 1 receptor antagonist. Tetrahedron Letters 1994; 35(32): 2939-5942.
54. 2+ channels. Eur J Pharmacol 1992; 215: 351-352.
55. Lowe III J A, Drozda S E, McLean S, Crawford R T, Bryce D K, Bordner J. N-alkyl quinuclidinium substance P antagonists. Biomed Chem Lett 1994; 4(9): 1153-1156.
56. Seward E M, Swain C J, Merchant K J et al. Quinuclidine based NK-1 antagonists 1: 3-benzyloxy-1-azabicyclo[2.2.2]octanes. Biomed Chem Lett 1993; 3(6): 1361-1366.
57. Swain C J, Seward E M, Sabin V et al. Quinuclidine based NK-1 antagonists 2: determination of the absolute stereochemical requirements. Biomed Chem Letters 1993; 3(8): 1703-1706.
58. 1 antagonists. J Med Chem 1995; 38(24): 4793-4805.
59. Lowe III J A, Ewing F E, Snider R M et al. 2-aryl-1-azabicyclo[2.2.2]octanes as novel nonpeptide substance P antagonists. Biomed Chem Lett 1994; 4(6): 839-842.
60. Desai M C, Lefkowitz S L, Thadeio P F, Longo K P, Snider R M. Discovery of a potent substance P antagonist: recognition of the key molecular determinant. J Med Chem 1992; 35: 4911-4913.
61. Desai M C, Lefkowitz S L, Bryce D K, McLean S. Articulating a pharmacophore driven synthetic strategy: discovery of a potent substance P antagonist Biomed Chem Lett 1994; 4(15): 1865-1868.
62. Desai M C, Vincent L A, Rizzi J P. Importance of parallel vectors and 'hydrophobic collapse' of the aligned aromatic rings: discovery of a potent substance P antagonist. J Med Chem 1994; 37(25): 4263-4266.
63. Armour D R, Watson S P, Pegg N A et al. Spiro-piperidine non-peptide neurokinin-1 receptor antagonists. Biomedical Chemistry Letters 1995; 5(22): 2671-2676.
64. Howard H R, Shenk K D, Coffman K C, Bryce D K, Crawford R T, McLean S A. Synthesis of conformationally restricted substance P antagonists. Biomed Chem Lett 1995; 5(2): 111-114.
65. Chan C, Cocker J D, Davies H G, Gore A, Green R H. Indolizidine derivatives as potential substance P antagonists. Biomedical Chemistry Letters 1996; 6(2): 161-164.
66. Cocker J D, Davies H G. Morphan based substance P antagonists. Biomed Chem Lett 1996; 6(1): 13-16.
67. 1 receptor antagonist, (2S, 3S)-(2-methoxy-5-tetrazol-1-ylbenzyl)(2-phenylpiperidin-3-yl)amine (GR203040), with potent antiemetic activity. J Med Chem 1995; 38(26): 4985-4992.
68. 1 receptor antagonist CP-99, 994 attenuates cisplatin induced emesis in the ferret. Biomed Chem Lett 1996; 6(9): 1015-1020.
69. 1 receptor. J. Pharmacol. Exp. Therap. 1996; 277: 900-908.
70. 1 antagonists 1: determination of the relative and absolute stereochemical requirements. Biomed Chem Lett 1994; 4(21): 2545-2550.
71. Harrison T, Williams B J, Swain C J. Gem-disubstituted aminoether based substance P antagonists. Biomed Chem Lett 1994; 4(23): 2733-2734.
72. Stevenson G I, MacLeod A M, Huscroft I, Cascieri M A, Sadowski S, Baker R. 4, 4-disubstituted piperidines: a new class of NK1 antagonists. J Med Chem 1995; 38(8): 1264-1266.
73. 1 anatgonists 2: investigation of the effect of N-substitution. Biomed Chem Lett 1995; 5(3): 209-212.
74. Mills S G, MacCoss M, Underwood D et al. 1, 2, 3-trisubstituted cyclohexyl substance P antagonists: significance of the ring nitrogen in piperidine-based NK-1 receptor antagonists. Biomed Chem Letters 1995; 5(13): 1345-1350.
75. 1 antagonists. J Med Chem 1996; 39(15): 2907-2914.
76. Hale J J, Mills S G, MacCoss M et al. 2(S)-((3, 5-bis (trifluoromethyl)benzyl)-oxy-3(S)phenyl-4-((3-oxo-1, 2, 4triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist. J Med Chem 1996; 39(9): 1760-1762.
77. Williams B J, Teall M, McKenna J et al. Acyclic NK-1 antagonists: 2-benzhydryl-2-aminoethyl ethers. Biomedical Chemistry Letters 1994; 4(16): 1903-1908.
78. Owens A P, Williams B J, Harrison T et al. Phenyl-glycinol based NK1 receptor antagonists - Towards the minimum pharmacophore. Biomedical Chemistry Letters 1995; 5(22): 2761-2766.
79. Teall M, Harrison T, Moseley J D, Owens A P, Sadowski S, Cascieri M A. Linear amide as substance P antagonists. Biomedical Chemistry Letters 1996; 6(13): 1585-1588.
80. 1 receptor antagonist. Eur J Pharmacol 1993; 250: 403-413.
81. 2) receptor. Life Sciences 1992; 50: PL101-PL106.
82. 1 receptor. Neuropharmacology 1994; 33(2): 167-179.
83. 2 receptors. Biomedical Chemistry Letters 1996; 6(8): 951-956.
84. 2 tachykinin receptor antagonist. J Pharmacol Exp Ther 1996; 277(3): 840-851.
85. Schilling W, Bittiger H, Brugger F et al. Approaches towards the design and synthesis of nonpeptidic substance P antagonists. Perspec Med Chem Basel, Verla Chimica Acta, 1993; 207-220.
86. 1 antagonist. Biomed Chem Lett 1996; 6(14): 1263-1268.
87. Mills S G, Wu M T, MacCoss M et al. 1, 4-diacylpiperazine-2-(S)-[N-aminoalkyl)carboxamides] as novel, potent substance P receptor antagonists. Biomed Chem Lett 1993; 3(12): 2707-2712.
88. Mills S G, MacCoss M, Cascieri M A et al. 1, 2, 4-triacylpiperidine substance P antagonists: separation of affinities for the NK-1 receptor and the L-type calcium channel. Biomed Chem Lett 1995; 5(6): 599-604.
89. MacLeod A M, Merchant K J, Cascieri M A et al. N-acyl-L-tryptophan benzyl esters: potent substance P receptor antagonists. J Med Chem 1993; 36(14): 2044-2045.
90. MacLeod A M, Merchant K J, Brookfield F et al. Identification of L-Tryptophan derivatives with potent and selective antagonist activity at the NK1 receptor. J Med Chem 1994; 37: 1269-1274.
91. 1 antagonists: conformationally constrained heterocyclic bioisosters of the ester linkage. J Med Chem 1995; 38(6): 923-933.
92. 1 antagonists derived from L-tryptophan. J Med Chem 1995; 38(6): 934-941.
93. 1 receptor antagonists. Biomed Chem 1994; 2(5): 357-370.
94. Horwell D C, Howson W, Ratcliffe G S, Rees D C. The design of a dipeptide library for screening at peptide receptor sites. Biomed Chem Lett 1993; 3(5): 799-802.
95. 2 receptor antagonists. Biomed Chem 1994; 2(2): 101-113.
96. Hipskind P A, Howbert J J, Bruns R F et al. 3-aryl-1, 2-diacetamidopropane derivatives as novel and potent NK-1 receptor antagonists. J Med Chem 1996; 39(3): 736-748.
97. Natsugari H, Ikeura Y, Kiyota Y, Ishichi Y et al. Novel, potent and orally active substance P antagonists: synthesis and antagonists activity of N-benzylcarboxamide derivatives of pyrido[3, 4-b]pyridine. J Med Chem 1995; 38(16): 3106-3120.
98. Gitter B D, Waters D C, Bruns R F, Mason N R, Nixon J A, Howbert J J. Species differences in affinities of nonpeptide antagonists for substance P receptors. Eur J Pharmacol 1991; 197: 237-238.
99. Sundelin J B, Provvedini D M, Wahlestedt C, Laurell H, Pohl J S, Peterson P A. Molecular cloning of the murine substance K and substance P receptor genes. Eur J Biochem 1992; 203: 625-631.
100. Gorbulev V, Akhundova A, Luzius H, Fahrenholz F. Molecular cloning of substance P cDNA from guinea-pig uterus. Biochim Biophys Acta 1992; 1131: 99-102.
101. Fong T M, Yu H, Strader C. Molecular bases for the species selectivity of the NK1 receptor antagonists CP 96345 and RP 67580. J Biol Chem 1992; 267: 25668-25671.
102. Sachais B S, Snider R M, Lowe III J A, Krause J E. Molecular basis for the species selectivity of the SP antagonist CP 96345. J Biol Chem 1993; 268: 2319-2323.
103. Jensen C J, Gerard N P, Schwartz T W, Gether U. The species selectivity of chemically distinct tachykinin nonpeptide antagonists is dependent on common divergent residues of the rat and human NK1 receptor. Mol Pharmacol 1994; 45: 294-299.
104. Pradier L, Habert-Ortoli E, Emile L et al. Molecular determinants of the species selectivity of NK1 receptor antagonists. Mol Pharmacol 1995; 47: 314-321.
105. Sachais B S, Krause J E. Both extracellular and transmembrane residues contribute to the species selectivity of the NK1 receptor antagonist WIN 51708. Mol Pharmacol 1994; 46: 122-128.
106. 1 receptor. J Biol Chem 1992; 267: 25664-25667.
107. 1 receptor and CP 96345, Nature 1993; 362: 350-353.
108. Zoffman S, Gether U, Schwartz T W. Conserved His VI-17 of the NK1 receptor is involved in binding of nonpeptide antagonists but not substance P. FEBS Letters 1993; 336: 506-510.
109. Fong T M, Yu H, Cascieri M A, Underwood D, Swian C J, Strader C D. The role of Histidine 265 in antagonist binding to the NK1 receptor. J Biol Chem 1994; 269: 2728-2732.
110. 1 receptor. Biochemistry 1994; 33: 3007-3013.
111. 1 receptor. J Biol Chem 1994; 269: 6587-6591.
112. 1 receptor with quinuclidine antagonists. J Biol Chemistry 1994; 269: 14957-14961.
113. Cascieri M A, Shiao L L, Mills S G et al. Characterization of the interaction of diacyl piperazine antagonists with the human NK1 receptor : identification of a common binding site for structurally dissimilar antagonists. Mol Pharmacol 1995; 47: 660-665.
114. 1 receptor for SP and a nonpeptide antagonist. Nature 1993; 362: 345-348.
115. 2 receptors. Proc Natl Acad Sci USA 1993; 90: 6194-6198.
116. 1 receptor involved in binding of the nonpeptide antagonist CP 96345. J Biol Chemistry 1994; 269: 23959-23964.
117. Schwartz T W, Gether U, Schambye H T, Hjorth S A. Molecular mechanism of action of nonpeptide ligands for peptide receptors. Current Pharmaceutical Design 1995; 1: 355-372.
118. 1 receptor. Nature 1995; 374: 740-77.
119. 1 receptor affect SP competition with nonpeptide antagonists but not SP binding. J Biol Chem 1994; 269: 28160-28164.
120. Guard S, Watson S P. Tachykinin receptor types: classification and membrane signalling mechanisms. Neurochem Int 1991; 18: 149-165.
121. Mac Donald S G, Boyd N D. Regulation of substance P receptor affinity by guanine nucleotide binding proteins. J Neurochem 1989; 53: 264-272.
122. Kwatra M M, Schwinn D A, Schreurs J et al. The substance P receptor, which couples to Gq/11, is a substrate of b-adrebergic receptor kinase 1 and 2. J Biol Chem 1993; 268: 9161-9164.
123. Mochizuki-Oda N, Nakajima Y, Nakanishi S, Ito S. Characterization of the SP receptor-mediated Ca influx in cDNA transfected CHO cells. J Biol Chem 1994; 269: 9651-9658.
124. 1) receptor to the a subnits of the G proteins Gq and G11. Biochemistry 1996; 35: 2909-2916.
125. 1 receptor. Biochemistry 1995; 34 : 16467-16472
126. Nakajima Y, Tsuchida K, Negishi M, Ito S, Nakanishi S. Direct linkage of three tachykinin receptors to stimulation of both phosphatidylinositol hydrolysis and cAMP cascades in transfected chinese hamster ovary cells. J Biol Chem 1992; 267: 2437-2442.
127. Mitsuhashi M, Ohashi Y, Shichijo S et al. Multiple intracellular signaling pathways of the neuropeptide SP receptor. J Neurosci Res 1992; 32: 437-443.
128. Takeda Y, Blount P, Sachais B S, Hershey A D, Raddatz R, Krause J E. Ligand binding kinetics of substance P and neurokinin A receptors stably expressed in CHO cells and evidence for differential stimulation of inositol 1, 4, 5-triphosphate and cAMP second messenger responses. J Neurochem 1992; 59: 740-745.
129. 1 (long) receptors expressed in CHO cells. Neurosci Lett 1993; 152: 9-12.
130. Garcia M, Sakamoto K, Shigekawa M, Nakanishi S, Ito S. Multiple mechanisms of arachidonic acid release in chinese hamster ovary cells transfected with cDNA of SP receptor. Biochem Pharmacol 1994; 48: 1735-1741.
131. Sun X P, Supplisson S, Mayer E. Chloride channels in myocytes from rabbit colon are regulated by a pertussis toxin-sensitive G protein. Am J Physiol 1993; 264: G774-G785.
132. Mau S E, Saermark T. Substance P stimulation of polyphosphoinositide hydrolysis in rat anterior pituitary membranes involves a GTP-dependent mechanism. J Endocrinol 1991; 130: 63-70.
133. Nakajima Y, Nakajima S, Inoue M. Pertussis toxin-insensitive G protein mediates substance P-induced inhibition of potassium channels in brain neurons. Proc Natl Acad Sci USA 1988; 85: 3643-3647
134. Schumann M A, Gardner P. Modulation of membrane K conductance in T-lymphocytes by SP via a GTP-binding protein. J Membr Biol 1989; 111: 133-139.
135. Koyano K, Velimirovic B M, Grigg J J, Nakajima S, Nakajima Y. Two signal transduction mechanisms of SP-induced depolarization of locus coeruleus neurons. Eur J Neurosci 1993; 5: 1189-1197.
136. 2 type tachykinin receptors. J Biol Chem 1993; 268: 16388-16395.
137. 1 receptor. Biochemistry 1994; 33: 3007-3013.
138. 1 receptor is important for coupling high affinity agonist binding to multiple second messenger responses. Mol Pharmacol 1995; 47: 1065-1071.
139. 1 receptors. J Pharmacol Exp Ther 1996; 276: 1039-1048.
140. Sugiya H, Tennes K A, Putney J W. Homologous desensitization of SP induced inositol polyphosphate formation in rat parotid acinar cells. Biochem J 1987; 244: 647-653.
141. 1) receptor expressed in epithelial cells. Biochem J 1994; 303: 177-186.
142. 1 receptors at sites of inflammation. Proc Natl Acad Sci USA 1994; 91: 8964-8968.
143. 1 receptor. Mol Biol Cell 1995; 6: 509-524.
144. Mantyh P W, Allen C J, Ghilardi J R, et al. Rapid endocytosis of a G-protein coupled receptor: SP-evoked internalization of its receptor in the rat striatum in vivo. Proc Natl Acad Sci USA 1995; 92: 2622-2626.
145. 1 and NK2 receptors. Mol Pharmacol 1996; 49: 438-446.
146. Barr A J, Watson S P. Protein kinase C mediates delayed inhibitory feedback regulation of human NK1 receptor activation of phospholipase C in UC11 astrocytoma cells. Mol Pharmacol 1994; 46: 266-273.
147. Simmons M A, Schneider C R, Krause J E. Regulation of the responses to gonadotropin-releasing hormone, muscarine and substance P in sympathetic neurons by changes in cellular constituents and intracellular application of peptide fragments of the substance P receptor. J Pharmacol Exp Ther 1994; 271: 581-589.
148. Sasakawa N, Sharif M, Hanley M R. Attenuation of agonistinduced desensitization of the rat SP receptor by progressive truncation of the C-terminus. FEBS Letters 1994; 347: 181-184.
149. Takeda Y, Chou K B, Takeda J, Sachais B S, Krause J E. Molecular cloning, structural characterization and functional expression of the human substance P receptor. Biochem Biophys Res Commun 1991; 179: 1232-1240.
150. 1): organization of the gene, chromosome localization and functional expression of cDNA clones. Biochemistry 1991; 30: 10640-10646.
151. 1 receptor cDNA. Biochem Biophys Res Commun 1991; 180: 1110-1117
152. Fong T M, Anderson S, Yu H, Huang R R C, Strader C D. Differential activation of intracellular effector by two isoforms of human NK1 receptor. Mol Pharmacol 1992; 41: 24-30.
153. Kage R, Leeman S E, Boyd N D. Biochemical characterization of two different forms of the substance P receptor in rat submaxillary gland. J Neurochem 1993; 60: 347-351.
154. 1 (SP) receptor in vivo. Brain Res 1996; 719: 8-13.